Investment manager bet big on PTCT stock, adds 41,000 shares, according to recent SEC filing

Palo Alto Investors LP reported a purchase of 41,303 shares of PTC therapeutics (NASDAQ:PTCT) in its SEC filing on February 17, 2026, with an estimated transaction value of $3.00 million based on quarterly average prices.

According to SEC file dated February 17, 2026 Palo Alto Investors LP increased its position in PTC Therapeutics by 41,303 shares during Q4 2025. The estimated transaction value for the additional shares was $3.00 million, based on quarter’s average closing prices. The fund’s holdings in PTC Therapeutics were valued at $68.66 million at the end of the quarter, up $15.72 million from the previous period, a change that reflects both rising holdings and price appreciation.

Palo Alto Investors LP reported a buy; PTC Therapeutics represents 9.56% of 13F reportable AUM as of December 31, 2025.

Main funds after presentation:

NASDAQ:INSM: $85.19M (11.9% of AUM)
NASDAQ: FOLD: $74.13M (10.3% of AUM)
NASDAQ:PTCT: $68.66M (9.6% of AUM)
NASDAQ:ACAD: $66.35M (9.2% of AUM)
NASDAQ:BMRN: $44.35M (6.2% of AUM)

As of February 17, 2026, shares of PTC Therapeutics were priced at $69.17, up 39.9% year-to-date, outperforming the S&P 500 by 21.57 percentage points.

metric	value
Revenue (TTM)	806.78 million dollars
net income (TTM)	($363.30 million)
Market capitalization	5.58 billion dollars
Price (as of market close on 2/17/26)	$69.17

It offers marketed therapies such as Translarna and Emflaza for Duchenne muscular dystrophy, Tegsedi and Waylivra for rare diseases and Evrysdi for spinal muscular atrophy, with additional candidates in development.
It operates a biopharmaceutical model focused on the discovery, development and commercialization of medicines for rare disorders, generating revenue primarily from product sales and strategic partnerships.
It serves patients with rare diseases, targeting healthcare providers, hospitals and specialty clinics in North America, Europe, Latin America and select international markets.

PTC Therapeutics, Inc. is a biotechnology company specializing in treatments for rare diseases, leveraging a strong portfolio of commercial products and research candidates. The company’s strategic partnerships and focus on high-need therapeutic areas support its competitive position in the rare disease market. With a global reach and emphasis on innovation, PTC Therapeutics aims to address unmet medical needs and drive long-term growth through continued investment in R&D.

Palo Alto Investors, a California-based investment firm, recently bought 41,000 shares of PTC Therapeutics, a biotech company. Here’s what average investors should know.

In my view, the biotech sector can be a challenging environment for retail investors. Biotech stocks often rise and fall based on the progress, or lack thereof, of the company’s treatment pipeline. The Food and Drug Administration (FDA) approval process plays an important role, as do clinical trials. Both activities introduce an element of volatility.

Therefore, many retail investors may be better served by being diversified Biotechnology Exchange Traded Fund (ETF). By doing so, it will insulate investors from the dizzying highs and lows that come from being highly exposed to a single biotech stock.

In short, biotech stocks can be a tricky sector for many retail investors. For those looking to invest in the industry, a sector-focused ETF could be a smart long-term play.

Before you buy shares of Ptc Therapeutics, consider this:

The Motley Fool Stock Advisor The team of analysts has just identified what they think they are 10 best stocks because investors are buying now… and Ptc Therapeutics was not one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you would have $523,599!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you would have $1,118,640!*

Now, it’s worth noting Stock advisor The total average performance is 951%: Outperformed the market compared to 194% for the S&P 500. Don’t miss the latest top 10 list, available with Stock advisorand join an investment community created by individual investors for individual investors.

See the 10 actions »

*Stock Advisor returns from March 3, 2026.

Jake Lerch has no position in any of the aforementioned stocks. The Motley Fool recommends AnaptysBio and BioMarin Pharmaceutical. The Motley Fool has one disclosure policy.

Investment manager bet big on PTCT stock, adds 41,000 shares, according to recent SEC filing was originally published by The Motley Fool

Source link